- $677.97m
- $625.73m
- $73.24m
- 99
- 16
- 86
- 75
Annual cashflow statement for Iradimed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1.37 | 9.33 | 12.8 | 17.2 | 19.2 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 3.89 | 1.58 | 1.54 | 2.59 | 2.52 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.17 | -1.58 | -5.06 | -5.91 | 3.75 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 5.82 | 11.3 | 10 | 13.5 | 25.6 |
| Capital Expenditures | -0.637 | -0.742 | -1.88 | -8.01 | -8.82 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.884 | 1.39 | 0.5 | 0 | — |
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0.247 | 0.648 | -1.38 | -8.01 | -8.82 |
| Financing Cash Flow Items | -1.21 | -0.599 | -0.294 | -0.61 | -0.688 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.522 | 0.024 | -12.7 | -13.7 | -14.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.59 | 11.9 | -4.04 | -8.2 | 2.47 |